{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:11:38Z","timestamp":1790770298617,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Although vaccines are available, rabies still claims more than 55,000 human lives each year. In most cases, rabies vaccines are given to humans after their exposure to a rabid animal; pre-exposure vaccination is largely reserved for humans at high risk for contacts with the virus. Most cases of human rabies are transmitted by dogs. Dog rabies control by mass canine vaccination campaigns combined with intensive surveillance programs has led to a decline of human rabies in many countries but has been unsuccessful in others. Animal vaccination programs are also not suited to control human rabies caused by bat transmission, which is common in some Central American countries. Alternatively, or in addition, more widespread pre-exposure vaccination, especially in highly endemic remote areas, could be implemented. With the multiple dose regimens of current vaccines, pre-exposure vaccination is not cost effective for most countries and this warrants the development of new rabies vaccines, which are as safe as current vaccines, but achieve protective immunity after a single dose, and most importantly, are less costly. This chapter discusses novel rabies vaccines that are in late stage pre-clinical testing or have undergone clinical testing and their potential for replacing current vaccines.<\/jats:p>","DOI":"10.3390\/vaccines7020054","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:49:59Z","timestamp":1561027799000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["New Rabies Vaccines for Use in Humans"],"prefix":"10.3390","volume":"7","author":[{"given":"Hildegund C. J.","family":"Ertl","sequence":"first","affiliation":[{"name":"The Wistar Institute, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J.D., Briggs, D.J., and Cleaveland, S. (2015). Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003786"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.03.023","article-title":"Successful strategies implemented towards the elimination of canine rabies in the Western Hemisphere","volume":"143","author":"Escobar","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.20506\/rst.37.2.2816","article-title":"Strategies for controlling dog-mediated human rabies in Asia: using \u201cOne Health\u201d principles to assess control programmes for rabies","volume":"37","author":"Yang","year":"2018","journal-title":"Rev. Off. Int. Epizoot."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.prevetmed.2018.07.011","article-title":"The epidemiology of dog rabies in Algeria: Retrospective national study of dog rabies cases, determination of vaccination coverage and immune response evaluation of three commercial used vaccines","volume":"158","author":"Yahiaoui","year":"2018","journal-title":"Prev. Vet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1590\/S1020-49892009000300010","article-title":"Rabies transmitted by vampire bats to humans: an emerging zoonotic disease in Latin America?","volume":"25","author":"Schneider","year":"2009","journal-title":"Rev. Panam. Salud Publica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3201\/eid1208.050929","article-title":"Bat-transmitted human rabies outbreaks, Brazilian Amazon","volume":"12","author":"Kotait","year":"2006","journal-title":"Emerging Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"Kessels","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/viro.1995.0049","article-title":"Immune effector mechanisms required for protection to rabies virus","volume":"214","author":"Xiang","year":"1995","journal-title":"Virology"},{"key":"ref_9","unstructured":"WHO Rabies vaccines (2007). WHO position paper. Wkly. Epidemiol. Rec., 82, 425\u2013435."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Moore, S.M., and Hanlon, C.A. (2010). Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000595"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shipley, R., Wright, E., Selden, D., Wu, G., Aegerter, J., Fooks, A.R., and Banyard, A.C. (2019). Bats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EU. Trop. Med. Infect. Dis., 4.","DOI":"10.3390\/tropicalmed4010031"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.1016\/j.vaccine.2012.10.015","article-title":"Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?","volume":"30","author":"Evans","year":"2012","journal-title":"Vaccine"},{"key":"ref_13","unstructured":"(2019, June 19). Rabies vaccines and immunoglobulins: WHO position April 2018. Available online: https:\/\/www.who.int\/immunization\/policy\/position_papers\/pp_rabies_summary_2018.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lewnard, J.A., and Cobey, S. (2018). Immune History and Influenza Vaccine Effectiveness. Vaccines (Basel), 6.","DOI":"10.3390\/vaccines6020028"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Desselberger, U. (2017). Differences of Rotavirus Vaccine Effectiveness by Country: Likely Causes and Contributing Factors. Pathogens, 6.","DOI":"10.3390\/pathogens6040065"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/21645515.2015.1119345","article-title":"Impact of host genetic polymorphisms on vaccine induced antibody response","volume":"12","author":"Linnik","year":"2016","journal-title":"Hum Vaccin. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1542\/peds.2013-3937","article-title":"Stool microbiota and vaccine responses of infants","volume":"134","author":"Huda","year":"2014","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jiu182","article-title":"Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis","volume":"210","author":"Parker","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ngugi, J.N., Maza, A.K., Omolo, O.J., and Obonyo, M. (2018). Epidemiology and surveillance of human animal-bite injuries and rabies post-exposure prophylaxis, in selected counties in Kenya, 2011-2016. BMC Public Health, 18.","DOI":"10.1186\/s12889-018-5888-5"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/2277-9531.112682","article-title":"Epidemiology of animal bite in Aq Qala city, northen of Iran","volume":"2","author":"Charkazi","year":"2013","journal-title":"J. Educ. Health Promot."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11908-014-0394-0","article-title":"Rabies in travelers","volume":"16","author":"Gautret","year":"2014","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1708-8305.2006.00097.x","article-title":"Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine","volume":"14","author":"Malerczyk","year":"2007","journal-title":"J. Travel. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2016.01.019","article-title":"Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods","volume":"225","author":"Vrdoljak","year":"2016","journal-title":"J. Control. Release."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpb.2014.11.024","article-title":"Phase 1 clinical study with Bioneedles, a delivery platform for biopharmaceuticals","volume":"89","author":"Hirschberg","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/jphp.12367","article-title":"Next generation vaccines: single-dose encapsulated vaccines for improved global immunisation coverage and efficacy","volume":"67","author":"Walters","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Amssoms, K., Born, P.A., Beugeling, M., De Clerck, B., Van Gulck, E., Hinrichs, W.L.J., Frijlink, H.W., Grasmeijer, N., Kraus, G., and Sutmuller, R. (2018). Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202961"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jconrel.2015.07.029","article-title":"Single-injection vaccines: Progress, challenges, and opportunities","volume":"219","author":"McHugh","year":"2015","journal-title":"J. Control Release."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0264-410X(98)00196-0","article-title":"Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells","volume":"17","author":"Sakamoto","year":"1999","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12250-016-3734-4","article-title":"Immunogenicity of multi-epitope-based vaccine candidates administered with the adjuvant Gp96 against rabies","volume":"31","author":"Niu","year":"2016","journal-title":"Virol. Sin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virusres.2016.05.007","article-title":"A novel rabies virus lipopeptide provides a better protection by improving the magnitude of DCs activation and T cell responses","volume":"221","author":"Liu","year":"2016","journal-title":"Virus Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virusres.2005.03.011","article-title":"Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity","volume":"111","author":"Morimoto","year":"2005","journal-title":"Virus Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1348-0421.2005.tb03692.x","article-title":"Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain","volume":"49","author":"Ito","year":"2005","journal-title":"Microbiol. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1038\/cti.2016.22","article-title":"Toll-like receptors: the swiss army knife of immunity and vaccine development","volume":"5","author":"Dowling","year":"2016","journal-title":"Clin. Transl. Immunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1016\/j.vaccine.2013.07.034","article-title":"Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIXTM adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques","volume":"31","author":"DiStefano","year":"2013","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1016\/j.vaccine.2018.07.006","article-title":"Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants","volume":"36","author":"Shi","year":"2018","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2015.10.029","article-title":"A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies","volume":"489","author":"Zhang","year":"2016","journal-title":"Virology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.vaccine.2016.12.031","article-title":"An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers","volume":"35","author":"Wijaya","year":"2017","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1016\/j.vaccine.2017.10.097","article-title":"A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen","volume":"35","author":"Kalimuddin","year":"2017","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1348-0421.1998.tb02270.x","article-title":"Antigenic and functional analyses of glycoprotein of rabies virus using monoclonal antibodies","volume":"42","author":"Luo","year":"1998","journal-title":"Microbiol. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Liu, X., Yang, Y., Sun, Z., Chen, J., Ai, J., Dun, C., Fu, Z.F., Niu, X., and Guo, X. (2014). A recombinant rabies virus encoding two copies of the glycoprotein gene confers protection in dogs against a virulent challenge. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087105"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.vaccine.2004.09.001","article-title":"TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines","volume":"23","author":"Tudor","year":"2005","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1471-4906(02)02259-7","article-title":"Of mice and men: species variations of Toll-like receptor expression","volume":"23","author":"Rehli","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.immuni.2016.09.011","article-title":"Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA","volume":"45","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature04734","article-title":"Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses","volume":"441","author":"Kato","year":"2006","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.vaccine.2015.03.036","article-title":"NIAID HIV Vaccine Trials Network Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials","volume":"33","author":"Jin","year":"2015","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1006\/viro.1994.1105","article-title":"Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus","volume":"199","author":"Xiang","year":"1994","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0264-410X(96)00281-2","article-title":"Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection","volume":"15","author":"Ray","year":"1997","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0264-410X(97)88325-9","article-title":"Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection","volume":"16","author":"Lodmell","year":"1998","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0264-410X(01)00392-9","article-title":"One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination","volume":"20","author":"Lodmell","year":"2001","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0264-410X(98)00328-4","article-title":"Immunization of dogs and cats with a DNA vaccine against rabies virus","volume":"17","author":"Osorio","year":"1999","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0264-410X(03)00568-1","article-title":"Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine","volume":"22","author":"Bahloul","year":"2003","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/S0264-410X(00)00475-8","article-title":"Post-exposure DNA vaccination protects mice against rabies virus","volume":"19","author":"Lodmell","year":"2001","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0264-410X(02)00143-3","article-title":"Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers","volume":"20","author":"Lodmell","year":"2002","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_60","first-page":"797","article-title":"Immunogenicity, efficacy and reactogenicity of a human diploid cell strain (HDCS) rabies vaccine in man; recommendations for pre- and post-exposure application (vaccination scheme) (author\u2019s transl)","volume":"72","author":"Kuwert","year":"1977","journal-title":"Med. Klin."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2009.09.090","article-title":"A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab)","volume":"28","author":"Ashwathnarayana","year":"2009","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.170.3.1416","article-title":"A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag","volume":"170","author":"Fitzgerald","year":"2003","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.4049\/jimmunol.0900317","article-title":"Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens","volume":"182","author":"Tatsis","year":"2009","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.4049\/jimmunol.175.9.6032","article-title":"Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors","volume":"175","author":"Hensley","year":"2005","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13567-017-0459-9","article-title":"Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG\u00ae): a global review","volume":"48","author":"Maki","year":"2017","journal-title":"Vet. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/JVI.02470-12","article-title":"A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein","volume":"87","author":"Amann","year":"2013","journal-title":"J. Virol."},{"key":"ref_67","unstructured":"(2009). Centers for Disease Control and Prevention (CDC) Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb. Mortal. Wkly. Rep., 58, 1204\u20131207."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1056\/NEJMoa010560","article-title":"Human infection due to recombinant vaccinia-rabies glycoprotein virus","volume":"345","author":"Rupprecht","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0264-410X(95)00171-V","article-title":"Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system","volume":"14","author":"Fries","year":"1996","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1128\/JVI.77.17.9553-9566.2003","article-title":"Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods","volume":"77","author":"Rux","year":"2003","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.00450-10","article-title":"Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae","volume":"84","author":"Chen","year":"2010","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7589\/0090-3558-45.2.363","article-title":"Aerial distribution of ONRAB baits as a tactic to control rabies in raccoons and striped skunks in Ontario, Canada","volume":"45","author":"Rosatte","year":"2009","journal-title":"J. Wildl. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7589\/0090-3558-48.1.157","article-title":"Comparing ONRAB\u00ae AND RABORAL V-RG\u00ae oral rabies vaccine field performance in raccoons and striped skunks, New Brunswick, Canada, and Maine, USA","volume":"48","author":"Rudd","year":"2012","journal-title":"J. Wildl. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1996.0239","article-title":"A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier","volume":"219","author":"Xiang","year":"1996","journal-title":"Virology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/JVI.76.6.2667-2675.2002","article-title":"Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product","volume":"76","author":"Xiang","year":"2002","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","article-title":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","volume":"450\u2013451","author":"Xiang","year":"2014","journal-title":"Virology"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wang, C., Dulal, P., Zhou, X., Xiang, Z., Goharriz, H., Banyard, A., Green, N., Brunner, L., Ventura, R., and Collin, N. (2018). A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLoS Negl. Trop. Dis., 12.","DOI":"10.1101\/408013"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/hum.2014.007","article-title":"Challenges in manufacturing adenoviral vectors for global vaccine product deployment","volume":"25","author":"Vellinga","year":"2014","journal-title":"Hum. Gene Ther."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/2\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:59:50Z","timestamp":1760187590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/2\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":79,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["vaccines7020054"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7020054","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}